QNCX Quince Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: QNCX

Price (delayed)

$1.48

Market cap

$53.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.54

Enterprise value

$9.11M

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence ...

Highlights
The debt has shrunk by 100% QoQ and by 100% YoY
The quick ratio has soared by 54% from the previous quarter
The equity has decreased by 15% YoY and by 3.8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cortexyme.com

Key stats

What are the main financial stats of QNCX
Market
Shares outstanding
36.28M
Market cap
$53.69M
Enterprise value
$9.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$51.38M
EBITDA
-$51.17M
Free cash flow
-$44.1M
Per share
EPS
-$1.54
Free cash flow per share
-$1.32
Book value per share
$2.78
Revenue per share
$0
TBVPS
$2.93
Balance sheet
Total assets
$103.91M
Total liabilities
$3.32M
Debt
$0
Equity
$100.59M
Working capital
$90.68M
Liquidity
Debt to equity
0
Current ratio
30.55
Quick ratio
29.38
Net debt/EBITDA
0.87
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-46.2%
Return on equity
-48.8%
Return on invested capital
-95.7%
Return on capital employed
-50.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QNCX stock price

How has the Quince Therapeutics stock price performed over time
Intraday
-0.67%
1 week
75.86%
1 month
57.75%
1 year
-75.21%
YTD
132.19%
QTD
132.19%

Financial performance

How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$52.02M
Net income
-$51.66M
Gross margin
N/A
Net margin
N/A
The net income rose by 43% YoY and by 26% QoQ
QNCX's operating income is up by 42% year-on-year and by 25% since the previous quarter

Growth

What is Quince Therapeutics's growth rate over time

Valuation

What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 49% year-on-year and by 31% since the previous quarter
QNCX's P/B is 34% below its last 4 quarters average of 0.8
The equity has decreased by 15% YoY and by 3.8% QoQ

Efficiency

How efficient is Quince Therapeutics business performance
The ROIC has increased by 30% year-on-year and by 27% since the previous quarter
The ROE has increased by 25% YoY and by 23% QoQ
Quince Therapeutics's ROA has increased by 21% YoY and by 21% from the previous quarter

Dividends

What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QNCX.

Financial health

How did Quince Therapeutics financials performed over time
QNCX's total liabilities has plunged by 77% YoY and by 37% from the previous quarter
The current ratio has soared by 54% from the previous quarter
The debt is 100% lower than the equity
The debt has shrunk by 100% QoQ and by 100% YoY
The equity has decreased by 15% YoY and by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.